Christopher J. Bungard

Merck & Co., Inc., Rahway, NJ, USA (United States)

Chemistry

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Activity of Tricyclic Pyrrolopyrimidine Gyrase B Inhibitor against Mycobacterium abscessus”.

Activity of Tricyclic Pyrrolopyrimidine Gyrase B Inhibitor against Mycobacterium abscessus

bioRxiv (Cold Spring Harbor Laboratory)(2022)10.1101/2022.05.16.492225

N/A

0.165DataRank · unranked

2 citations

Dereje A. Negatu, Abdellatif El Marrouni, Randy R. Miller, Christopher W. Boyce, Nicholas Murgolo +7 more

Activity of Tricyclic Pyrrolopyrimidine Gyrase B Inhibitor against Mycobacterium abscessus

Antimicrobial Agents and Chemotherapy(2022)10.1128/aac.00669-22

N/A

0DataRank · unranked

10 citations

Dereje A. Negatu, Abdellatif El Marrouni, Randy R. Miller, Christopher W. Boyce, Nicholas Murgolo +7 more

Pharmacological validation of dihydrofolate reductase as a drug target in Mycobacterium abscessus

Antimicrobial Agents and Chemotherapy(2023)10.1128/aac.00717-23

N/A

0DataRank · unranked

15 citations

Dereje A. Negatu, Christopher J. Bungard, Véronique Dartois, Abdellatif El Marrouni, Elliott Nickbarg +4 more